Kuala lumpur: Bioeconomy Corporation aims to generate at least RM2.2 billion in revenue from companies under its BioNexus Status and Bio-based Accelerator (BBA) programmes in 2026, said chief executive officer Mohd Khairul Fidzal Abdul Razak in a statement today.
According to BERNAMA News Agency, the target aligns with the MADANI Government's priorities, with plans to adopt digital and artificial intelligence (AI)-enabled solutions to help companies scale and accelerate growth more efficiently. The integration of AI across agriculture, healthcare, and industrial bioeconomy sectors is anticipated to bolster food security, advance healthcare innovation, support the circular economy, and unlock new economic opportunities.
Mohd Khairul highlighted that since 2005, Bioeconomy Corporation has offered comprehensive support to companies, including investment promotion, SME and talent development, market access, and funding facilitation, in accordance with the National Science, Technology and Innovation Policy 2021-2030. Over the past five years, more than 560 industry players have been trained to enhance regulatory and tax compliance, talent management, and access to funding, leading to the creation of Malaysia's first biotechnology unicorn in 2024.
The corporation has also enabled 18 BioNexus Status companies to achieve public listings on local and international exchanges, including in New York, London, and Australia, and facilitated more than 1,900 job opportunities through its BeST 2.0 programme since 2021. Additionally, the Malaysian Bioeconomy Development Corporation has contributed RM39.9 billion to Malaysia's gross domestic product (GDP) over the past 20 years, reinforcing its role as a key driver of the nation's biotechnology and bio-based industries.
Operating under the Ministry of Science, Technology and Innovation (MOSTI), the agency has facilitated over RM14.6 billion in approved investments, created more than 16,600 jobs nationwide, and supported nearly 650 companies through its BioNexus Status and BBA programmes. Science, Technology and Innovation Minister Chang Lih Kang emphasized that the corporation's 20-year milestone reflects the government's confidence in its role to lead Malaysia's bioeconomy towards global competitiveness, particularly under the National Biotechnology Policy (NBP) 2.0.
In 2025 alone, estimated investment and commercial value captured under Bioeconomy Corporation's facilitation increased from RM1.55 billion in 2024 to over RM2.44 billion, representing nearly 60 percent growth. With support from MOSTI, Bioeconomy Corporation continues to drive progress under NBP 2.0, aspiring to position Malaysia as a high-technology bioinnovation nation by 2030.
The ministry is confident that even greater value will be achieved in the coming years, particularly as the organisation sharpens its focus over the next five years on six high-value, high-growth sub-sectors: next-generation proteins, regenerative propagation, sustainable materials, bio-based chemicals, regenerative medicine, and precision diagnostics. This strategic direction supports the 13th Malaysia Plan (2026-2030), contributing to economic growth through blue, green, and silver economy initiatives.